FELIQS Corporation

About FELIQS Corporation

FELIQS Corporation is a preclinical-stage start-up focused on developing novel medicines targeting ferroptosis and oxidized lipids. Their mission is to create a society without people left behind by addressing unmet medical needs in ophthalmology and solving problems related to pediatric and aging diseases in an aging society with a declining birthrate.

Products & Services

FLQ-101:A drug targeting Retinopathy of Prematurity (ROP), administered intravenously or orally, currently in preclinical and IND-enabling stages.

FLQ-105:A drug targeting Geographic Atrophy and wet AMD, administered orally, currently in discovery/research and lead optimization stages.

Specialties

Ferroptosis and oxidized lipid research Drug discovery for ophthalmology Preclinical research for unmet medical needs

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 9000000 MR: - FA: $9 million FAN: 9000000	D: 2025-07-01 FD: 2025-07-01	6 investors

Series A Latest

2025-07-01

$9.0M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

K

Kenichiro "Nobu" Kuninobu

Co-founder and CEO, Ph.D.

K

Ken-ichiro Kuninobu

Representative Director, Co-founder & CEO

LinkedIn (Pro only)

M

MaryJane Rafii

Director, Business Development & Finance

R

Robert Armenti

Clinical Trial Manager

A

Antoinette Mancini

Consulting Research Nurse

C

Christian Ofslager

CMC Expert

View 20 more team members with Pro

Unlock Full Team Directory

Recent News